The Cancer Letter

Inside information on cancer research and drug development

In Brief

Cancer Support Community Benjamin Center presents awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CANCER SUPPORT COMMUNITY BENJAMIN CENTER presented its annual Gilda Award Gala in Los Angeles. The organization honored actress Frances Fisher with the Gilda Award; CSC advocate Joyce Green with the Wellness Award; and City of Hope’s Matthew Loscalzo with the Harold H. Benjamin Innovation Award.

The event was hosted by John Sencio, a national television host, producer and cancer survivor.

Loscalzo is the Liliane Elkins Professor in Supportive Care Programs, professor in the Department of Population Sciences, executive director of the Department of Supportive Care Medicine, and the administrative director of the Sheri & Les Biller Patient and Family Resource Center at the City of Hope-National Medical Center.

Fisher has starred in over 30 theatrical productions and was honored for promoting wellness and generosity. Green served as director of development for Cancer Support Community Benjamin Center.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account